Selected Scientific Presentations

Since 2020

2022

Eingeladener Beitrag zur Sitzung des Ausschuss Klinische Forschung des Bundesverbands der Pharmazeutischen Industrie (BPI)
Berlin, Germany, September 13, 2022:

Michael Schlander:

"The Cost of New Drug Development"

(Presentation available on request)

EbM Congress 2022
Online-Pre-Conference, Germany, March 18, 2022:

Andrea Gaisser, Rachel Eckford, Evelyn Kludt, Michael Baumann, Susanne Weg-Remers, Michael Schlander:

"Auswirkungen der Corona-Pandemie für Krebsbetroffene und ihre Versorgung: Ergebnisse einer Befragungsstudie"

(Online Poster Presentation available on request)

2021

20. Deutscher Kongress für Versorgungsforschung (DKVF)
Berlin / Germany, October 06-08, 2021:

Andrea Gaisser, Rachel Eckford, Michael Baumann, Evelyn Kludt, Susanne Weg-Remers, Michael Schlander:

Impact of the corona pandemic on cancer patients: Results from a German cross-sectional pilot study.

(Poster Presentation available on request)

Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (DGHO)
Hybrid Event, Berlin / Germany, October 01-04, 2021:

Rachel Eckford, Andrea Gaisser, Volker Arndt, Michael Baumann, Evelyn Kludt, Katja Mehlis, Jasper Ubels, Eva Winkler, Susanne Weg-Remers, Michael Schlander:

Online survey of cancer patients on changes in care and on psycho-social burden during the pandemic.

(Poster Presentation available on request)

2020

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Virtual ISPOR Europe, November 16 – November 19, 2020:

Jeff Richardson, Marteen Postma, Soren Holm, Michael Schlander:

Social Cost Value Analysis: Do we need an alternative health economic evaluation paradigm?

(Online Panel Session)
Conference proceedings from Virtual ISPOR Europe 2020.

Michael Schlander, Tao Ran, Patrick Schmidt, Stefan Eichmüller:

The acquisition cost and efficiency of CAR T-cell therapies: can they be improved by decentralized manufacturing?

(Online Research Poster Presentation)
Value in Health (2020), 23(S2): S460.

Ramon Schaefer, Diego Hernandez, Michael Schlander:

The role of the budget impact: A multivariate analysis of health technology assessment (HTA) outcomes by GBA/IQWiG in Germany and NICE in England.

(Online Research Poster Presentation)
Value in Health (2020), 23(S2): S530.

Karla Hernandez-Villafuerte, Michael Schlander, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz, Michael Baumann:

How much does it cost to research & develop a new drug? A systematic review and evaluation of 40 years of literature.

(Online Research Poster Presentation)
Value in Health (2020), 23(S2): S756.

Rachel Eckford, Karla Hernandez-Villafuerte, Leander Hirschberg, Michael Schlander:

A systematic review of the socioeconomic impact of cancer on patients and families: Are differences among countries being effectively captured and addressed?

(Online Research Poster Presentation)
Value in Health (2020), 23(S2): S478.

Chih-Yuan Cheng, Silvia Calderazzo, C Schramm, Michael Schlander:

Modeling the duration of protective effects and resource use of colonoscopy screening by a discrete event simulation model calibrated with German screening registry data.

(Online Research Poster Presentation)
Value in Health (2020), 23(S2): S456-457.

German, Austrian and Swiss Associations of Hematology and Medical Oncology (DGHO)
October 09 – October 11, 2020:

Anett Molnar, Titus Brinker, Tanja Jutzki, Karla Hernandez-Villafuerte, Michael Schlander:

Direct and indirect cost of malignant cutaneous melanoma in European countries – Results of a literature review.

(Abstract Video Presentation)
DGHO Annual Meeting 2020.

European Society for Medical Oncology (ESMO)
ESMO Virtual Congress, September 19 – September 21, 2020:

Michael Schlander, Tao Ran, Patrick Schmidt, Stefan Eichmüller:

Can we reduce the acquisition cost of CAR T-cell therapies?

(Online Research Poster Presentation)
Annals of Oncology (2020), 31(S4): S966.

Ramon Schaefer, Diego Hernandez, Michael Schlander:

Health technology assessment (HTA) in England, France and Germany: What do we know about variations in cancer-related HTA outcomes?

(Online Presentation)
Annals of Oncology (2020), 31(S4): S1197.

Karla Hernandez-Villafuerte, Michael Schlander, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz, Michael Baumann:

How much does it cost to research and develop a new medicine? A systematic review and evaluation of 40 years of literature.

(Online Research Poster Presentation)
Annals of Oncology (2020), 31(S4): S962.

Chih-Yuan Cheng, Silvia Calderazzo, C Schramm, Michael Schlander:

Modelling the long-term effectiveness of colonoscopy screening by a discrete event simulation model calibrated with German screening registry data.

(Online Research Poster Presentation)
Annals of Oncology (2020), 31(S4): S457-458.

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
Virtual ISPOR, May 18 – May 20, 2020:

Ramon Schaefer, Diego Hernandez, Michael Schlander:

´Advancing evidence to action´: A comparison of health technology assessment (HTA) outcomes in England, France and Germany.

(Online Research Poster Presentation)
Value in Health (2020), 23(S1): S70.

Diego Hernandez, Michael Schlander:

Income loss after a cancer diagnosis in Germany: an analysis based upon the socio-economic panel survey.

(Online Research Poster Presentation)
Value in Health (2020), 23(S1): S76.

Rachel Eckford, Karla Hernandez-Villafuerte, Leander Hirschberg, Michael Schlander:

The social and socioeconomic impact ofcancer on patients and their families: A systematic review.

(Online Research Poster Presentation)
Value in Health (2020), 23(S1): S78.